[go: up one dir, main page]

CY1117481T1 - Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης - Google Patents

Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης

Info

Publication number
CY1117481T1
CY1117481T1 CY20161100273T CY161100273T CY1117481T1 CY 1117481 T1 CY1117481 T1 CY 1117481T1 CY 20161100273 T CY20161100273 T CY 20161100273T CY 161100273 T CY161100273 T CY 161100273T CY 1117481 T1 CY1117481 T1 CY 1117481T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
kinolin
product
composition containing
formula
Prior art date
Application number
CY20161100273T
Other languages
English (en)
Inventor
Masashi Bando
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117481(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1117481T1 publication Critical patent/CY1117481T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Αποκαλύπτεται μια φαρμακευτική σύνθεση η οποία περιέχει: μια ένωση που αντιπροσωπεύεται από τον τύπο (I), ένα φαρμακολογικώς αποδεκτό άλας αυτής, ή ένα διαλύτωμα της ένωσης ή άλατος, και μια βασική ουσία. Η φαρμακευτική σύνθεση έχει εξαιρετική ικανότητα διαλύτωσης, είναι σταθερή ακόμη και μετά από μακροχρόνια αποθήκευση, και είναι χρήσιμη ως προφυλακτικός/θεραπευτικός παράγοντας για όγκους. (Στον τύπο, το R1 αντιπροσωπεύει ένα άτομο υδρογόνου, μια C1-6 αλκυλ ομάδα ή μια C3-8 κυκλοαλκυλ ομάδα, και το R2 αντιπροσωπεύει ένα άτομο υδρογόνου ή μια μεθοξυ ομάδα).
CY20161100273T 2009-08-19 2016-04-05 Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης CY1117481T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009190145 2009-08-19
EP10809938.3A EP2468281B1 (en) 2009-08-19 2010-08-16 Quinoline derivative-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
CY1117481T1 true CY1117481T1 (el) 2017-04-26

Family

ID=43607048

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100273T CY1117481T1 (el) 2009-08-19 2016-04-05 Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης

Country Status (33)

Country Link
US (3) US20120077842A1 (el)
EP (1) EP2468281B1 (el)
JP (1) JP5048871B2 (el)
KR (1) KR101496395B1 (el)
CN (1) CN102470133B (el)
AU (1) AU2010285740C1 (el)
BR (1) BR112012003592B8 (el)
CA (1) CA2771403C (el)
CL (1) CL2012000412A1 (el)
CO (1) CO6440512A2 (el)
CY (1) CY1117481T1 (el)
DK (1) DK2468281T3 (el)
ES (1) ES2564797T3 (el)
HK (2) HK1167607A1 (el)
HR (1) HRP20160283T1 (el)
HU (1) HUE026957T2 (el)
IL (1) IL217197A (el)
MA (1) MA33581B1 (el)
ME (1) ME02359B (el)
MX (2) MX2012002011A (el)
MY (1) MY162940A (el)
NZ (1) NZ598291A (el)
PE (1) PE20121030A1 (el)
PL (1) PL2468281T3 (el)
RS (1) RS54686B1 (el)
RU (1) RU2548673C3 (el)
SG (1) SG178009A1 (el)
SI (1) SI2468281T1 (el)
SM (1) SMT201600077B (el)
TH (1) TH121482A (el)
UA (1) UA105671C2 (el)
WO (1) WO2011021597A1 (el)
ZA (1) ZA201108697B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP1938842A4 (en) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
CA2627598C (en) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (ko) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CA2704000C (en) * 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CN106139156B (zh) * 2014-11-14 2019-01-29 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN106075456A (zh) * 2015-04-27 2016-11-09 南京圣和药业股份有限公司 一种含乐伐替尼的药物组合物及其应用
EP3287444A4 (en) * 2015-05-21 2018-09-12 Crystal Pharmatech Co., Ltd. New crystal form of lenvatinib methanesulfonate salt and preparation method thereof
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN106999483B (zh) * 2015-08-17 2019-05-03 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
KR102587702B1 (ko) 2015-08-20 2023-10-12 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
CZ2016240A3 (cs) 2016-04-27 2017-11-08 Zentiva, K.S. Soli lenvatinibu
PL3384901T3 (pl) 2017-04-04 2025-01-13 Synthon B.V. Kompozycja farmaceutyczna zawierająca mesylan lenwatynibu
JP2020519576A (ja) 2017-05-16 2020-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療
US10583133B2 (en) 2018-03-12 2020-03-10 Shilpa Medicare Limited Pharmaceutical compositions of lenvatinib
CN110404079B (zh) * 2018-04-27 2023-01-24 北京睿创康泰医药研究院有限公司 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物
CA3113549A1 (en) * 2018-10-04 2020-04-09 Synthon B.V. Crystalline forms and processes of lenvatinib besylate
PT3632436T (pt) 2018-10-04 2022-07-22 Synthon Bv Composição farmacêutica compreendendo sais de lenvatinib
CN113087666B (zh) * 2020-01-09 2021-12-14 南京正大天晴制药有限公司 无定形喹啉甲酰胺衍生物的制备方法
CN113491695A (zh) * 2020-03-18 2021-10-12 上海博志研新药物技术有限公司 一种仑伐替尼药物组合物、其制备方法及应用
EP4147689A1 (en) 2021-09-13 2023-03-15 Lotus Pharmaceutical Co., Ltd. Lenvatinib formulation
CN114306271B (zh) * 2021-11-24 2023-04-07 石药集团中奇制药技术（石家庄）有限公司 一种仑伐替尼组合物
CN115671074B (zh) * 2022-11-15 2024-06-04 郑州德迈药业有限公司 一种甲磺酸仑伐替尼制剂及其制备方法
EP4424303A1 (en) 2023-02-28 2024-09-04 Stada Arzneimittel Ag Lenvatinib composition with improved bioavailability

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458148A (en) * 1974-04-19 1976-12-08 Wyeth John & Brother Ltd Carbocyclic-fused ring quinoline derivatives
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
RU2264389C3 (ru) * 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
ES2534713T3 (es) * 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1556356B1 (en) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
CN101337932B (zh) 2003-12-25 2011-06-08 卫材R&D管理有限公司 喹啉羧酰胺的甲磺酸盐的结晶(b)及其制备方法
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CN101233111A (zh) * 2005-06-23 2008-07-30 卫材R&D管理有限公司 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
US7550483B2 (en) * 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2009111648A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies

Also Published As

Publication number Publication date
MA33581B1 (fr) 2012-09-01
BR112012003592B8 (pt) 2021-05-25
NZ598291A (en) 2013-02-22
MX344927B (es) 2017-01-11
JP5048871B2 (ja) 2012-10-17
EP2468281B1 (en) 2016-01-27
WO2011021597A1 (ja) 2011-02-24
RU2548673C3 (ru) 2018-07-20
RS54686B1 (en) 2016-08-31
JPWO2011021597A1 (ja) 2013-01-24
SI2468281T1 (sl) 2016-05-31
ES2564797T3 (es) 2016-03-29
BR112012003592A2 (pt) 2016-03-15
SG178009A1 (en) 2012-03-29
US20210228722A1 (en) 2021-07-29
KR101496395B1 (ko) 2015-02-26
CN102470133B (zh) 2013-08-28
CA2771403C (en) 2015-02-24
PE20121030A1 (es) 2012-08-18
EP2468281A1 (en) 2012-06-27
ZA201108697B (en) 2012-07-25
CO6440512A2 (es) 2012-05-15
UA105671C2 (uk) 2014-06-10
IL217197A0 (en) 2012-02-29
US20130296365A1 (en) 2013-11-07
AU2010285740C1 (en) 2016-03-17
HK1169599A1 (zh) 2013-02-01
US20120077842A1 (en) 2012-03-29
SMT201600077B (it) 2016-04-29
KR20120055559A (ko) 2012-05-31
CN102470133A (zh) 2012-05-23
MX2012002011A (es) 2012-03-26
BR112012003592B1 (pt) 2020-11-03
TH121482A (th) 2013-02-28
AU2010285740A1 (en) 2011-12-15
HK1167607A1 (en) 2012-12-07
PL2468281T3 (pl) 2016-06-30
ME02359B (me) 2016-06-20
HUE026957T2 (en) 2016-07-28
HRP20160283T1 (hr) 2016-05-06
CA2771403A1 (en) 2011-02-24
DK2468281T3 (en) 2016-03-21
IL217197A (en) 2016-08-31
AU2010285740B2 (en) 2014-12-04
EP2468281A4 (en) 2013-01-23
MY162940A (en) 2017-07-31
RU2012103471A (ru) 2013-09-27
CL2012000412A1 (es) 2012-08-31
RU2548673C2 (ru) 2015-04-20

Similar Documents

Publication Publication Date Title
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
CY1122944T1 (el) Ορισμενες αμινο-πυριμιδινες, συνθεσεις αυτων, και μεθοδοι για χρηση αυτων
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
PH12017501192A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
MX2010006421A (es) Compuestos organicos.
CY1115301T1 (el) Παραγωγα ισοξαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου
CU24030B1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR083492A1 (es) Derivados aminicos para el tratamiento de trastornos proliferativos de la piel
MX2011011716A (es) Derivados de isoquinolina novedosos.
CU20120041A7 (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY32702A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.
JO3123B1 (ar) مشتقات كينولين-تحتوي على مركبات دوائية
CY1115610T1 (el) Μορφολινο πυριμιδινες και η χρηση τους στη θεραπεια
MX2009000254A (es) Nuevos derivados de 1h-indol-1-il-urea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CY1115546T1 (el) Ετεροκυκλικα σουλφοναμιδια, χρησεις και φαρμακευτικες συνθεσεις αυτων
CY1114642T1 (el) Παραγωγα αδαμαντυλο διαμιδιου και χρησεις αυτων
UY32895A (es) Derivados acetilénicos de 5-fenilpirazolopiridina, su preparación y su aplicación terapéutica
AR060285A1 (es) Derivados de enfumafungina y sus sales farmaceuticamente aceptables, su sintesis y su uso como inhibidores de (1,3)-b-d-glucanosintetasa
TH106979A (th) อนุพันธ์ของแอลคิล พิริมิดิน-4-โอนที่ถูกแทนที่
TH150702A (th) อนุพันธ์ไพราซีน (Pyrazine Derivatives) ในรูปตัวบลอค ENaC
AR078424A1 (es) Derivados de dihidroimidazoquinolina con actividad inhibitoria de tafia, composiciones farmaceuticas que los contienen y su uso como agentes terapeuticos o profilacticos para enfermedades tromboticas